Stockscreener 앱 받기
13.34
7.93%
0.98
시간 외 거래:
13.40
0.06
+0.45%
전일 마감가:
$12.36
열려 있는:
$12.48
하루 거래량:
1.92M
Relative Volume:
2.94
시가총액:
$480.49M
수익:
$10.00M
순이익/손실:
$-75.99M
주가수익비율:
-5.5879
EPS:
-2.3873
순현금흐름:
$-80.36M
1주 성능:
+0.38%
1개월 성능:
-33.03%
6개월 성능:
-17.65%
1년 성능:
+0.00%
1일 변동 폭
$12.36
$13.84
1주일 범위
$12.07
$13.90
52주 변동 폭
$12.07
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
13.34 | 445.19M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 재개 | Oppenheimer | Outperform |
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune, Inc. (EVMN) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga
EVMNEvommune Inc Options - Finviz
Evommune, Inc. (NYSE: EVMN) Stock Price, News & Analysis - Kalkine
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market - TipRanks
Evommune’s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN) - Seeking Alpha
Evommune drops on phase 2 data for EVO756 in urticaria - MSN
Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development - The Dermatology Digest
Evommune shares plunge 38% after lead drug fails Phase 2b trial; insiders sold shares days before news. - Pluang
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) - PR Newswire
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - The Globe and Mail
Evommune stock downgraded by H.C. Wainwright after trial failure - Investing.com South Africa
EVMN Maintained by Morgan Stanley -- Price Target Lowered to $26 - GuruFocus
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Evommune Inc : RBC Cuts Target Price to $30 F - Moomoo
A Quick Look at Today's Ratings for Evommune(EVMN.US), With a Forecast Between $26 to $28 - Moomoo
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes - BioSpace
HC Wainwright Downgrades Evommune to Neutral From Buy - marketscreener.com
Evommune drops EVO756 in CSU after Phase IIb failure - The Pharma Letter
Evommune terminates oral drug’s development in CSU - Clinical Trials Arena
Evommune (EVO) Faces Setback as EVO756 Fails Key Trial for Chron - GuruFocus
Sectoral Asset Management Inc's Evommune Inc(EVMN) Holding History - GuruFocus
Evommune shares slide after phase 2b CSU trial misses main goal (EVMN) - MSN
Evommune, Inc. Stock 12‑Month Price Target Cut to $39.33, Implies 56% Upside - TradingView
EVMN Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Evommune Still Has Shot At Atopic Dermatitis With EVO756 After Urticaria Failure - insights.citeline.com
Evommune stock rating cut to Market Perform by William Blair - Investing.com UK
Less than a year after IPO, Evommune stock is getting pummeled — here's why - The Business Journals
Evommune, Inc.(NYSE: EVMN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why is Evommune stock plummeting today? By Investing.com - Investing.com India
Evommune, Inc.(NYSE: EVMN) dropped from Russell 2500 Value Benchmark - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Evommune's EVO756 Misses Primary End Point in Phase 2b CSU Trial, Development Continues in AD and Migraine - Dermatology Times
Why is Evommune stock plummeting today? - Investing.com UK
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Evommune's Skin Disorder Study Falls Short - Benzinga
Evommune slips as oral drug fails mid-stage urticaria study - FirstWord Pharma
Evommune’s EVO756 Fails Phase 2b in Chronic Spontaneous Urticaria but Advances in Atopic Dermatitis and Migraine Trials – Minichart - Minichart
Evommune (EVMN) Reports Phase 2b Trial Results for EVO756 - GuruFocus
Raymond James cuts Evommune stock rating on trial miss By Investing.com - Investing.com Nigeria
Raymond James cuts Evommune stock rating on trial miss - Investing.com
Evommune Inc (EVMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Evommune Inc 주식 (EVMN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Sale |
22.63 |
20,000 |
452,600 |
67,794 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Option Exercise |
3.84 |
1,488 |
5,714 |
47,891 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Sale |
22.50 |
1,488 |
33,480 |
46,403 |
| Pena Luis C. | President & CEO |
Jun 22 '26 |
Sale |
22.71 |
7,438 |
168,917 |
630,458 |
1.17%
2.48%
자본화:
|
볼륨(24시간):